ForSight Robotics, an Israel-based startup in ophthalmic robotic surgery field, has completed a $125 million Series B round, led by Eclipse. The investment accelerates the next growth phase for the ORYOM™ Platform, the world’s first robotic surgery platform for cataract and other eye diseases designed to enhance surgical precision, increase patient access to high-quality treatment, and decrease the physical burden on surgeons, as the company prepares to launch first-in-human clinical trials this year.
In addition to Eclipse, the funding round included significant participation from an undisclosed strategic investor, as well as Dr Fred Moll, the Adani Group, Reiya Ventures, and other existing investors – bringing ForSight Robotics’ total funding to $195 million.
The ORYOM™ platform is engineered for highly precise and consistent ophthalmic procedures, beginning with cataract. Utilising artificial intelligence (AI)-based algorithms, advanced computer vision, and micromechanics, the robotic surgery platform aims to deliver unprecedented dexterity and maneuverability while providing surgeons with an improved ergonomic experience. The ORYOM™ Platform can reach any point within the human eye, allowing surgeons to navigate complex angles and ensuring access to both anterior and posterior segments, setting the stage for glaucoma and retinal surgical treatment.
Globally, there are only 31.7 ophthalmologists per million population and 14.1 cataract surgeons per million population. By 2035, the industry expects a 12% decline in ophthalmologists, while demand is projected to increase by 24%. At the same time, over 600 million patients suffer from cataract, and only 30 million of these patients receive surgical treatment.
